Molbio Diagnostics, specializes in providing accessible, high-quality healthcare solutions, primarily through their Truenat platform. Truenat is a point-of-care, portable, battery-operated real-time PCR (polymerase chain reaction) system. This technology enables rapid and accurate molecular diagnostics directly at primary health centers, field locations, and other non-laboratory settings, decentralizing access to crucial diagnostic services.
Truenat has gained significant recognition, including endorsement from the World Health Organization (WHO) as a replacement for smear microscopy in diagnosing tuberculosis (TB). The platform can test for over 40 diseases, including COVID-19, hepatitis, HIV, HPV, and vector-borne diseases like dengue, chikungunya, and malaria. Truenat's technology is designed to operate independently of complex infrastructure, making it suitable for deployment in remote and underserved areas.
Molbio Diagnostics recently secured $85 million in funding from Temasek and Motilal Oswal Alternates, boosting its valuation to $1.6 billion and earning it the "unicorn" status. This funding will help the company develop and commercialize more near-care technologies and expand the global reach of the Truenat platform.
Truenat Platform
The Truenat system is designed for rapid, on-site molecular diagnostics. Key features include:
Portability and Battery Operation: Enables use in various settings, including primary health centers and field locations.
Real-Time PCR: Provides quick and accurate diagnostics.
Wide Range of Assays: Capable of testing for over 40 infectious diseases such as tuberculosis (TB), COVID-19, hepatitis, HIV, HPV, and vector-borne diseases like dengue, chikungunya, and malaria.
Recognition and Impact
WHO Endorsement: The World Health Organization has endorsed Truenat as a replacement for smear microscopy for TB diagnosis, highlighting its effectiveness and reliability.
Global Deployment: Truenat systems are in use in over 5,000 testing centers across more than 40 countries. In India, these devices are deployed under the National Tuberculosis Elimination Programme and other international health initiatives.
Strategic Goals
Technological Advancements: Continuous innovation in point-of-care diagnostics to improve early disease detection and treatment.
Market Reach: Expanding the availability of Truenat systems to underserved regions worldwide.
Sustainability: Developing solutions that are sustainable and address global healthcare challenges.
Recent Funding and Expansion
Unicorn Status: Molbio Diagnostics joined the unicorn club with a valuation of $1.6 billion after raising $85 million from Temasek and Motilal Oswal Alternates.
Expansion Plans: The recent funding will support the development and commercialization of additional near-care technologies, facilitating further expansion into global markets. The company's focus remains on addressing clinical need gaps and enhancing healthcare infrastructure.